Should I buy or sell HilleVax stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HilleVax in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HLVX shares. View HLVX analyst ratings or view top-rated stocks .

What is HilleVax's stock price target for 2024?

3 brokerages have issued 12-month target prices for HilleVax's stock. Their HLVX share price targets range from $28.00 to $34.00. On average, they expect the company's stock price to reach $30.67 in the next twelve months. This suggests a possible upside of 149.3% from the stock's current price. View analysts price targets for HLVX or view top-rated stocks among Wall Street analysts .

How have HLVX shares performed in 2024?

HilleVax's stock was trading at $16.05 on January 1st, 2024. Since then, HLVX shares have decreased by 23.4% and is now trading at $12.30. View the best growth stocks for 2024 here .

Are investors shorting HilleVax?

HilleVax saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 448,200 shares, a decrease of 5.6% from the March 15th total of 474,900 shares. Based on an average trading volume of 124,700 shares, the short-interest ratio is currently 3.6 days. Approximately 2.9% of the shares of the company are short sold. View HilleVax's Short Interest .

When is HilleVax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our HLVX earnings forecast .

How were HilleVax's earnings last quarter?

HilleVax, Inc. (NASDAQ:HLVX) released its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.02.

What ETFs hold HilleVax's stock?

ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Morningstar US Small Growth (MSGR) . Amplify Treatments, Testing and Advancements ETF (GERM) .

When did HilleVax IPO?

HilleVax (HLVX) raised $200 million in an IPO on Friday, April 29th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share.

How do I buy shares of HilleVax?

Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HLVX

HilleVax (HLVX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free HLVX Stock Alerts

$12.30

+0.44 (+3.71%)

(As of 04/19/2024 ET)

Compare

Today's Range: $11.73
▼
$12.50
50-Day Range: $11.86
▼
$19.75
52-Week Range: $9.94
▼
$20.22

Volume: 276,760 shs
Average Volume: 137,798 shs
Market Capitalization: $611.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.67

Get HilleVax alerts:

HilleVax MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 149.3% Upside
$30.67 Price Target
Short Interest: Healthy
2.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.89
Based on 4 Articles This Week
Insider Trading: Selling Shares
$986.46 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.22) to ($3.38) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.65 out of 5 stars

Medical Sector

240th out of 911 stocks

Biological Products, Except Diagnostic Industry

32nd out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
HilleVax has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
HilleVax has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.90% of the float of HilleVax has been sold short.
Short Interest Ratio / Days to Cover
HilleVax has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in HilleVax has recently decreased by 5.62%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
HilleVax does not currently pay a dividend.
Dividend Growth
HilleVax does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HLVX.

3.3

News and Social Media Coverage

News Sentiment
HilleVax has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for HilleVax this week, compared to 1 article on an average week.
Search Interest
1 people have searched for HLVX on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added HilleVax to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, HilleVax insiders have sold 659,521.69% more of their company's stock than they have bought. Specifically, they have bought $149,550.00 in company stock and sold $986,464,242.00 in company stock.
Percentage Held by Insiders
29.30% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
86.42% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for HilleVax are expected to decrease in the coming year, from ($3.22) to ($3.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of HilleVax is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of HilleVax is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
HilleVax has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About HilleVax Stock (NASDAQ:HLVX)

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

HLVX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HLVX Stock News Headlines

April 9, 2024 | insidertrades.com

Insider Buying: HilleVax, Inc. (NASDAQ:HLVX) Major Shareholder Buys 8,850 Shares of Stock

April 7, 2024 | insidertrades.com

Aditya Kohli Sells 6,000 Shares of HilleVax, Inc. (NASDAQ:HLVX) Stock

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 2, 2024 | insidertrades.com

Sean Mcloughlin Acquires 1,250 Shares of HilleVax, Inc. (NASDAQ:HLVX) Stock

March 21, 2024 | insidertrades.com

HilleVax, Inc. (NASDAQ:HLVX) Director Sells $105,960.00 in Stock

April 18, 2024 | americanbankingnews.com

HilleVax, Inc. (NASDAQ:HLVX) Short Interest Down 5.6% in March

April 12, 2024 | americanbankingnews.com

Critical Contrast: AVROBIO (NASDAQ:AVRO) and HilleVax (NASDAQ:HLVX)

April 7, 2024 | investing.com

Hillevax director Aditya Kohli sells shares worth over $264k

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 22, 2024 | seekingalpha.com

HilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued Valuation

March 21, 2024 | markets.businessinsider.com

HilleVax, Inc’s HIL-214 Vaccine Candidate Promises Broad Protection Against Norovirus, Justifying Buy Rating

March 20, 2024 | benzinga.com

Recap: HilleVax Q4 Earnings

March 20, 2024 | finance.yahoo.com

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

March 20, 2024 | globenewswire.com

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

February 26, 2024 | msn.com

Janux stock soars 96% in after hours trading on updated drug data

February 23, 2024 | finance.yahoo.com

Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX)

February 13, 2024 | benzinga.com

Aditya Kohli's Net Worth

February 5, 2024 | finance.yahoo.com

HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

January 18, 2024 | markets.businessinsider.com

HilleVax Appoints GSK's Sean McLoughlin As COO

January 18, 2024 | finance.yahoo.com

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

January 8, 2024 | finance.yahoo.com

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

January 5, 2024 | benzinga.com

HilleVax Stock (NASDAQ:HLVX) Dividends: History, Yield and Dates

January 3, 2024 | finance.yahoo.com

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023 | finance.yahoo.com

Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 10,000 Shares of HilleVax Inc ...

December 14, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of HilleVax (HLVX) with Buy Recommendation

December 6, 2023 | finance.yahoo.com

Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 20,000 Shares of HilleVax Inc ...

November 30, 2023 | finance.yahoo.com

Wall Street Analysts Believe HilleVax, Inc. (HLVX) Could Rally 92.19%: Here's is How to Trade

See More Headlines

Receive HLVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:HLVX
CUSIP: N/A
CIK: 1888012
Web: www.hillevax.com
Phone: 617-213-5054
Fax: N/A
Employees: 90
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.67
High Stock Price Target: $34.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +149.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-123,570,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -48.17%
Return on Assets: -38.05%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 10.62
Quick Ratio: 10.62

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.48 per share
Price / Book: 2.24

Miscellaneous

Outstanding Shares: 49,720,000
Free Float: 35,153,000
Market Cap: $611.56 million
Optionable: Not Optionable
Beta: 0.65

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Robert M. Hershberg M.D. (Age 62)
Ph.D., President, CEO & Chairman of the Board
Comp: $1.02M
Dr. Aditya Kohli Ph.D. (Age 35)
Chief Business Officer & Director
Comp: $782.44k
Mr. Shane A. Maltbie (Age 42)
CFO & Treasurer
Mr. Sean McLoughlin (Age 52)
Chief Operating Officer
Dr. Anju Chatterji Ph.D.
Chief Technology Officer
Mr. Paul S. Bavier J.D. (Age 52)
General Counsel, Secretary & Chief Administrative Officer
Ms. Astrid Borkowski M.D. (Age 54)
Ph.D., Chief Medical Officer
Mr. Ozzie Berger
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HLVX Stock Analysis - Frequently Asked Questions

Should I buy or sell HilleVax stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HilleVax in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HLVX shares.
View HLVX analyst ratings or view top-rated stocks.
What is HilleVax's stock price target for 2024?: 3 brokerages have issued 12-month target prices for HilleVax's stock. Their HLVX share price targets range from $28.00 to $34.00. On average, they expect the company's stock price to reach $30.67 in the next twelve months. This suggests a possible upside of 149.3% from the stock's current price.
View analysts price targets for HLVX or view top-rated stocks among Wall Street analysts.
How have HLVX shares performed in 2024?: HilleVax's stock was trading at $16.05 on January 1st, 2024. Since then, HLVX shares have decreased by 23.4% and is now trading at $12.30.
View the best growth stocks for 2024 here.
Are investors shorting HilleVax?: HilleVax saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 448,200 shares, a decrease of 5.6% from the March 15th total of 474,900 shares. Based on an average trading volume of 124,700 shares, the short-interest ratio is currently 3.6 days. Approximately 2.9% of the shares of the company are short sold.
View HilleVax's Short Interest.
When is HilleVax's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our HLVX earnings forecast.

How were HilleVax's earnings last quarter?: HilleVax, Inc. (NASDAQ:HLVX) released its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.02.
What ETFs hold HilleVax's stock?: ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Morningstar US Small Growth (MSGR).Amplify Treatments, Testing and Advancements ETF (GERM).
When did HilleVax IPO?: HilleVax (HLVX) raised $200 million in an IPO on Friday, April 29th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share.
How do I buy shares of HilleVax?: Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HLVX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial